Midwest Regional Medical Center, LLC
Midwest Regional Medical Center, LLC was paid $5.30M by Medicaid between Jan 2018 and Sep 2021, across 62 billing codes. Its largest line is 99284, emergency room visit (serious) — 41% of everything it billed.
MIDWEST CITY, OK 73110
Next to other Cardiovascular Disease Physician providers in Oklahoma
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,959 | $1.57M | |
| 2019 | 18,915 | $1.45M | |
| 2020 | 15,138 | $1.33M | |
| 2021 | 11,496 | $941K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 41% | 9,884 | 9,623 | $2.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 8,790 | 8,586 | $1.27M |
| D9999 | Unspecified adjunctive procedure, by report | 7.8% | 462 | 462 | $411K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.7% | 3,440 | 3,343 | $407K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 768 | 761 | $213K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.4% | 1,675 | 1,621 | $127K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 1,489 | 1,480 | $126K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,279 | 2,186 | $87K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.4% | 1,416 | 1,400 | $73K |
| 80053 | Comprehensive metabolic panel | 1.2% | 6,504 | 6,342 | $64K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 1,270 | 1,258 | $57K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,996 | 6,790 | $52K |
50 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,307 | $50K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,641 | $34K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 299 | $30K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,604 | $17K |
| 87400 | <1% | 1,321 | $16K | |
| 81001 | <1% | 4,914 | $16K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 837 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 101 | $10K |
| 85027 | <1% | 1,111 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,806 | $6K |
| 80055 | <1% | 131 | $6K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 359 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 373 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 63 | $5K |
| 83690 | <1% | 571 | $4K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 120 | $3K |
| 80061 | Lipid panel | <1% | 212 | $3K |
| 84703 | <1% | 374 | $3K | |
| 87081 | <1% | 306 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 217 | $2K |
| 84439 | <1% | 209 | $2K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 45 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 50 | $2K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 227 | $2K |
| 97597 | <1% | 85 | $919.78 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14 | $718.34 |
| 83735 | <1% | 106 | $643.94 | |
| 82247 | <1% | 124 | $590.98 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,366 | $580.35 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 29 | $450.94 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13 | $437.43 |
| 84484 | <1% | 26 | $433.25 | |
| 83880 | <1% | 12 | $420.20 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 403 | $316.33 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 13 | $148.24 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 18 | $87.12 |
| 82950 | <1% | 16 | $77.12 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 513 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 12 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 392 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 530 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 214 | $0.00 |
| 36416 | 0% | 18 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 443 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 784 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 152 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 12 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.